Kala Pharmaceuticals (KALA) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Kala Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 6, 2020 7:00 AM EDT
-- EYSUVIS NDA Accepted by FDA; Assigned PDUFA Goal Date of October 30, 2020 --
-- 2Q 2020 INVELTYS® Revenue of $0.8 Million --
-- Conference Call and Webcast at 8:00 a.m. ET --
WATERTOWN, Mass.--(BUSINESS WIRE)-- Kala Pharmaceuticals, Inc. (NASDAQ: KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported financial results for the second quarter ended June 30, 2020.
We are very pleased with our progress in the second quarter, said Mark Iwicki,... More
